Skip to main content

Table 2 Baseline characteristics and treatment outcome of two cohorts

From: Pretreatment microRNA levels can predict HBsAg clearance in CHB patients treated with pegylated interferon α-2a

Characteristic

Identification Cohort (n = 20)

Confirmation Cohort (n = 47)

 

HBsAg clearance

Non-HBsAg clearance

p

HBsAg clearance

Non-HBsAg clearance

p

No.

10

10

17

30

Male sex, No.(%)

9 (90%)

7 (70%)

0.582

15 (88%)

24 (80%)

0.692

aAge, y

29 ± 8.9

46.4 ± 6.8

0.0001***

39 ± 7.7

38.7 ± 9.3

0.921

History of NAs

 Yes

6

7

1

10

22

0.305

 No

4

3

7

8

Combination of NAs

 Yes

4

4

1

5

8

0.84

 No

6

6

 

12

22

 

cHBV DNA, IU/ml

 undetectable (< 500)

7

9

0.582

16

23

0.228

 500~ 1000

3

1

1

7

bHBsAg at baseline, IU/ml

186.09 (29.31–724.35)

184.28 (62.75–536.69)

1

116.54 (33.36–195.26)

504.36 (156.35–875.49)

0.01

  < 500, No.

7

7

0.549$

14

15

0.09$

 500~ 1000, No.

2

3

2

10

 1000~ 1500, No.

1

0

1

5

aALT baseline level, IU/ml

36.4 ± 17.83

30.69 ± 9.9

0.388

31.51 ± 14.0

37.21 ± 30.65

0.474

aWBC,× 1012

6.12 ± 1.43

6.08 ± 1.37

0.951

5.98 ± 1.70

5.37 ± 1.28

0.176

Treatment outcome

bPEG-IFN treatment course, w

62.5 (49.8–70.8)

49.5 (39.3–59.5)

0.89

68 (48–72)

71 (48–72.75)

0.789

bHBsAg at EOT, IU/ml

0.01 (0–0.014)

228.3 (11.80–387.92)

1.53E-4***

0 (0–0.01)

20.86 (2.6–154.47)

1.5783E-8***

Follow-up weeks

56.3 (33.3–93.8)

45.6 (32.4–80)

0.241

25.6 (19.1–37.7)

23.6 (14.3–39.1)

0.542

bHBsAg at follow-up, IU/ml

0.015 (0–0.02)

184.26 (38.45–380.22)

1.44E-4***

0 (0–0.02)

28.11 (4.94–289.45)

1.637E-8***

  1. $a` = (2*a)/[k*(k-1) + 1] = 0.014, k = 3, a = 0.05; * p < 0.05, **p < 0.01, ***p < 0.001
  2. ALT alanine aminotransferase, WBC white blood count, EOT end of treatment. History of NAs means whether they have used nucles(t)ide analogs (NAs) before PEG-IFN treatment, the NAs include all kinds of conventional medicines: TDF, ETV, LAM, LdT, ADV. They were used by means of monotherapy or combined treatment. The median duration time of NAs was 64.60w (33.3–82.97) (median ± IQR)
  3. adata was presented as mean ± SD
  4. bdata was presented as median (IQR range)
  5. cHBV DNA < 500 IU/ml is undetected in our lab test